NRG-BN009 / RBRT21007 / Milano
Basic Study Information
Purpose:
This phase III trial compares the effect of adding whole brain radiotherapy with hippocampal
avoidance and memantine to stereotactic radiosurgery versus stereotactic radiosurgery
alone in treating patients with cancer that has spread to the brain and come back
in other areas of the brain after earlier stereotactic radiosurgery. Hippocampus avoidance
during whole-brain radiation therapy decreases the amount of radiation that is delivered
to the hippocampus, which is a brain structure that is important for memory. The medicine
memantine is also often given with whole brain radiation therapy because it may decrease
the risk of side effects of radiation on thinking and memory. Stereotactic radiosurgery
delivers a high dose of radiation only to the small areas of cancer in the brain and
avoids the surrounding normal brain tissue. Adding whole brain radiotherapy with hippocampal
avoidance and memantine to stereotactic radiosurgery may be effective in shrinking
or stabilizing cancer that has spread to the brain and returned in other areas of
the brain after receiving stereotactic radiosurgery.
Location: University of Rochester
Lead Researcher (Principal Investigator)
Lead Researcher:
Michael Milano
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search